<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00553592</url>
  </required_header>
  <id_info>
    <org_study_id>XTL B07-001</org_study_id>
    <nct_id>NCT00553592</nct_id>
  </id_info>
  <brief_title>Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With Diabetes</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Parallel, Multicenter Study of the Safety and Efficacy of Two Dosages of Bicifadine SR in Adult Outpatients With Chronic Neuropathic Pain Associated With Diabetic Peripheral Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XTL Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>XTL Biopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of two dosages (600mg/day and 1200mg/day) of bicifadine SR with
      placebo for 14 weeks in reduction of chronic neuropathic patin (measured by a daily rating of
      pain intensity) associated with diabetic periperal neuropathy in adult outpatients.

      To compare the tolerability of two dosages of bicifadine SR with placebo in adult outpaitens
      treated for chronic neuropathic pain for 14 weeks associated with diabetic peripheral
      neuropathy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2007</start_date>
  <completion_date type="Anticipated">December 2008</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain and Safety</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Improvement, McGill Pain Questionnaire, Amount of Rescue Medication Used for Pain, Quality of Life Survey (SF-36), Patient Global Impression of Change</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">336</enrollment>
  <condition>Diabetic Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bicifadine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bicifadine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of Bicifadine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicifadine</intervention_name>
    <description>600mg/day</description>
    <arm_group_label>Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicifadine</intervention_name>
    <description>placebo tablet</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicifadine</intervention_name>
    <description>1200 mg</description>
    <arm_group_label>Drug: 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 years or older

          -  Diagnosis of type-1 or type 2 non-insulin dependent diabetes mellitus

          -  Chronic bilateral pain due to diabetic neuropathy

          -  Pain for at least six months

          -  Primary pain is located in the feet

          -  Others-contact site for information

        Exclusion Criteria:

          -  Symptoms of other painful conditions

          -  Presence of amputations other than toes

          -  Clinically significant psychiatric or other neurological disorder

          -  Use of certain medications

          -  Clinically important other diseases

          -  Pregnancy

          -  History of alcohol or narcotic abuse within two years

          -  Others-contact site for information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Roffman, PhD</last_name>
    <role>Study Director</role>
    <affiliation>XTL Bio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ivy Raso</last_name>
    <phone>845-267-0707</phone>
    <phone_ext>222</phone_ext>
    <email>iraso@xtlbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kevin Barnes, MT</last_name>
    <phone>512-306-4254</phone>
    <email>kbarnes@incresearch.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Four Rivers Clinical Research</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesse Wallace, MD</last_name>
      <phone>270-441-4606</phone>
      <email>diargent@fourriversresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Caron Massey</last_name>
      <phone>270-441-4606</phone>
      <email>cmassey@fourriversresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jesse Wallace, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.xtlbio.com</url>
    <description>Sponsor's website</description>
  </link>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2007</study_first_submitted>
  <study_first_submitted_qc>November 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2007</study_first_posted>
  <last_update_submitted>November 2, 2007</last_update_submitted>
  <last_update_submitted_qc>November 2, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

